Class Action Lawsuit Filed Against TransMedics Group, Inc.
In a recent development, the law firm of Kirby McInerney LLP has announced the filing of a class action lawsuit against TransMedics Group, Inc. (TransMedics or the Company) in the U.S. District Court for the District of Massachusetts. The lawsuit alleges that TransMedics and certain of its executives violated the Securities Exchange Act of 1934 by making false and misleading statements and/or failing to disclose material information during the period from February 28, 2023, through January 10, 2025 (the Class Period).
Allegations Against TransMedics
The complaint alleges that TransMedics and its executives made false and misleading statements regarding the Company’s business, operations, and financial condition. Specifically, the lawsuit alleges that TransMedics failed to disclose: (1) that the Company was experiencing manufacturing issues with its Organ Care System (OCS), which could impact its revenue growth; (2) that the Company was experiencing delays in obtaining regulatory approvals for its OCS in Europe, which could impact its revenue growth; and (3) that the Company was experiencing increased competition in the cardiovascular and transplantation markets, which could impact its revenue growth.
Impact on TransMedics Shareholders
As a result of these alleged false and misleading statements, TransMedics shares traded at artificially inflated prices during the Class Period. When the truth was revealed, the price of TransMedics shares fell significantly, causing harm to investors. If you acquired TransMedics securities during the Class Period, you may be entitled to compensation.
Impact on the World
The implications of this lawsuit extend beyond TransMedics and its shareholders. TransMedics is a leading developer, manufacturer, and supplier of medical technologies for cardiovascular and transplantation procedures. The Company’s OCS is a revolutionary technology that allows for the preservation and transport of donor organs outside the body, extending the time available for transplantation and improving patient outcomes. The allegations in this lawsuit could impact the public’s perception of TransMedics and its technology, potentially hindering the Company’s ability to attract new customers and investors.
Next Steps for Affected Investors
If you acquired TransMedics securities during the Class Period, you have until April 15, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit. The lead plaintiff is a representative party who acts on behalf of all Class Members in the lawsuit. The lead plaintiff will be responsible for making important decisions in the lawsuit, including whether to accept a settlement or go to trial.
To learn more about the lawsuit and your potential eligibility to participate, you can contact Kirby McInerney LLP by email at [[email protected]](mailto:[email protected]) or by filling out the form on their website. You can also contact the firm by calling (212) 620-6690.
Conclusion
The filing of this class action lawsuit against TransMedics Group, Inc. is a significant development for investors in the Company’s securities during the Class Period. The allegations in the lawsuit could have a profound impact on TransMedics and its shareholders, as well as on the public’s perception of the Company and its technology. Affected investors are encouraged to contact Kirby McInerney LLP to learn more about their potential eligibility to participate in the lawsuit and to protect their investments.
- TransMedics Group, Inc. (TMDX)
- Class Action Lawsuit
- Securities Exchange Act of 1934
- False and Misleading Statements
- Violations
- Kirby McInerney LLP
- Lead Plaintiff
- April 15, 2025
